Nutcracker Therapeutics
Nutcracker Therapeutics is a biotechnology company based in Emeryville, CA that develops mRNA-based oncology therapeutics using a proprietary microfluidics-based manufacturing technology.[1] The company was founded in 2018 by Igor Khandros, Ph.D., and Benjamin Eldridge. Khandros currently serves as chief executive officer, with Eldridge as chief technology officer.
NTX-250, Nutcracker’s lead candidate, is a multimodal RNA therapeutic primarily for use against the HPV-driven cervical cancer precursor, cervical intraepithelial neoplasia[2]. As of 2023, NTX-250 is in the preclinical stage of development.
References
- ↑ Sheridan, Cormac (2022-08-01). "mRNA printers kick-start personalized medicines for all". Nature Biotechnology. 40 (8): 1160–1162. doi:10.1038/s41587-022-01430-y. ISSN 1546-1696. PMC 9362478 Check
|pmc=value (help). PMID 35945442 Check|pmid=value (help). - ↑ Gormley, Brian (2023-04-26). "RNA Medicines Startup Orbital Therapeutics Collects $270 Million". Wall Street Journal. ISSN 0099-9660. Retrieved 2023-12-11.
This article "Nutcracker Therapeutics" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Nutcracker Therapeutics. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
